Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy
- PMID: 22710579
- DOI: 10.1038/ajg.2012.113
Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy
Abstract
Objectives: Lactulose is effective in secondary prophylaxis of hepatic encephalopathy (HE). Probiotics improves minimal hepatic encephalopathy (MHE), which predisposes to HE. No study has been conducted on the secondary prophylaxis of HE using probiotics. Our objective was to study the effects of lactulose and probiotics for secondary prophylaxis of HE.
Methods: Consecutive cirrhotic patients who had recovered from HE were randomized to receive lactulose (Gp-L, 30 ml three times per day), three capsules of probiotics (Gp-P) per day containing 112.5 billion viable lyophilized bacteria per capsule, or no therapy (Gp-N). All patients were assessed by psychometry (number connection test (NCT-A, B), figure connection test if illiterate (FCT-A, B), digit symbol test (DST), and block design test (BDT)), critical flicker frequency (CFF) test, and arterial ammonia at inclusion. The patients were followed up monthly. The primary end point was development of overt HE according to West Haven criteria or a follow-up of 12 months.
Results: Of 360 patients who recovered, 235 (65.2%) met the inclusion criteria (Gp-L, n=80; Gp-P, n=77; and Gp-N, n=78). In all, 38 patients (16.1%) were lost to follow-up and 77 patients developed HE (Gp-L, n=18; Gp-P, n=22; and Gp-N, n=37). There was a significant difference between Gp-L and Gp-N (P=0.001) and between Gp-P and Gp-N (P=0.02) but no difference between the Gp-L and Gp-P groups (P=0.349). The rate of readmission for causes other than HE (Gp-L, Gp-P, and Gp-N, 19:21:28; P=0.134) and deaths (Gp-L:Gp-P:Gp-N=13:11:16; P=0.56) in all three groups were similar. There was a high prevalence of abnormal psychometry test results (NCT-A, 71.5%; NCT-B, 69.2%; DST, 76.9%; and BDT, 85.2%), and FCT-A and -B were abnormal in 35 of 48 patients (72.7%). CFF was <38 Hz in 118 patients (50.2%). Upon multivariate analysis, recurrence of overt HE was significantly associated with two or more abnormal psychometric tests and arterial ammonia after the recovery of an episode of HE.
Conclusions: Lactulose and probiotics are effective for secondary prophylaxis of HE in patients with cirrhosis.
Similar articles
-
Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.J Gastroenterol Hepatol. 2012 Aug;27(8):1329-35. doi: 10.1111/j.1440-1746.2012.07186.x. J Gastroenterol Hepatol. 2012. PMID: 22606978 Clinical Trial.
-
Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.Gastroenterology. 2009 Sep;137(3):885-91, 891.e1. doi: 10.1053/j.gastro.2009.05.056. Epub 2009 Jun 6. Gastroenterology. 2009. PMID: 19501587 Clinical Trial.
-
An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.Eur J Gastroenterol Hepatol. 2008 Jun;20(6):506-11. doi: 10.1097/MEG.0b013e3282f3e6f5. Eur J Gastroenterol Hepatol. 2008. PMID: 18467909 Clinical Trial.
-
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.Hepatobiliary Pancreat Dis Int. 2018 Feb;17(1):9-16. doi: 10.1016/j.hbpd.2018.01.005. Epub 2018 Feb 2. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29428113 Review.
-
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22. Clin Ther. 2013. PMID: 23972578 Review.
Cited by
-
Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials.Front Med (Lausanne). 2024 Mar 28;11:1379333. doi: 10.3389/fmed.2024.1379333. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38618195 Free PMC article.
-
Prophylaxis of hepatic encephalopathy: current and future drug targets.Hepatol Int. 2024 Aug;18(4):1096-1109. doi: 10.1007/s12072-024-10647-9. Epub 2024 Mar 16. Hepatol Int. 2024. PMID: 38492132 Review.
-
A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy.Medicina (Kaunas). 2023 Dec 10;59(12):2143. doi: 10.3390/medicina59122143. Medicina (Kaunas). 2023. PMID: 38138246 Free PMC article. Review.
-
Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure.Semin Liver Dis. 2023 Nov;43(4):429-445. doi: 10.1055/s-0043-1776773. Epub 2023 Dec 15. Semin Liver Dis. 2023. PMID: 38101419 Free PMC article. Review.
-
Ethanol-Producing Enterocloster bolteae Is Enriched in Chronic Hepatitis B-Associated Gut Dysbiosis: A Case-Control Culturomics Study.Microorganisms. 2023 Sep 28;11(10):2437. doi: 10.3390/microorganisms11102437. Microorganisms. 2023. PMID: 37894093 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
